WO2001025793A3 - Diagnosis of coeliac disease using a gliadin epitope - Google Patents

Diagnosis of coeliac disease using a gliadin epitope Download PDF

Info

Publication number
WO2001025793A3
WO2001025793A3 PCT/GB2000/003760 GB0003760W WO0125793A3 WO 2001025793 A3 WO2001025793 A3 WO 2001025793A3 GB 0003760 W GB0003760 W GB 0003760W WO 0125793 A3 WO0125793 A3 WO 0125793A3
Authority
WO
WIPO (PCT)
Prior art keywords
coeliac disease
epitope
seq
gliadin
sequence
Prior art date
Application number
PCT/GB2000/003760
Other languages
French (fr)
Other versions
WO2001025793A2 (en
Inventor
Robert Paul Anderson
Adrian Vivian Sinton Hill
Derek Parry Jewell
Original Assignee
Isis Innovation
Robert Paul Anderson
Adrian Vivian Sinton Hill
Jewell Dererk Parry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001528704A priority Critical patent/JP4932112B2/en
Priority to DK05027922T priority patent/DK1672368T3/en
Priority to EP00964460A priority patent/EP1218751B1/en
Priority to US10/089,700 priority patent/US7144569B1/en
Application filed by Isis Innovation, Robert Paul Anderson, Adrian Vivian Sinton Hill, Jewell Dererk Parry filed Critical Isis Innovation
Priority to AU75394/00A priority patent/AU782262B2/en
Priority to CA2386089A priority patent/CA2386089C/en
Priority to MXPA02003295A priority patent/MXPA02003295A/en
Priority to DE60026332T priority patent/DE60026332T2/en
Publication of WO2001025793A2 publication Critical patent/WO2001025793A2/en
Publication of WO2001025793A3 publication Critical patent/WO2001025793A3/en
Priority to CY20061100681T priority patent/CY1105282T1/en
Priority to US11/556,218 priority patent/US7888460B2/en
Priority to US11/556,208 priority patent/US8329144B2/en
Priority to US13/672,183 priority patent/US20130318648A1/en
Priority to US15/481,007 priority patent/US20180057547A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising : (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is : SEQ ID NO : 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO : 3, (ii) an epitope comprising sequence comprising : SEQ ID NO : 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO : 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided.
PCT/GB2000/003760 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope WO2001025793A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2386089A CA2386089C (en) 1999-10-01 2000-10-02 Diagnostic and therapeutic epitope and transgenic plant
EP00964460A EP1218751B1 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope
US10/089,700 US7144569B1 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope
DE60026332T DE60026332T2 (en) 1999-10-01 2000-10-02 DIAGNOSIS OF DOMESTIC SPRUE / CELIAC DISEASE WITH THE HELP OF GLIADINE PITOPENES
AU75394/00A AU782262B2 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope
DK05027922T DK1672368T3 (en) 1999-10-01 2000-10-02 Diagnostic and therapeutic epitope
MXPA02003295A MXPA02003295A (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope.
JP2001528704A JP4932112B2 (en) 1999-10-01 2000-10-02 Diagnostic and therapeutic epitopes and transgenic plants
CY20061100681T CY1105282T1 (en) 1999-10-01 2006-05-29 DIAGNOSIS OF COLONICCUS USING A GLIADIN SPOT
US11/556,218 US7888460B2 (en) 1999-10-01 2006-11-03 Diagnostic and therapeutic epitope, and transgenic plant
US11/556,208 US8329144B2 (en) 1999-10-01 2006-11-03 Diagnostic and therapeutic epitope, and transgenic plant
US13/672,183 US20130318648A1 (en) 1999-10-01 2012-11-08 Diagnosis and therapeutic epitope, and transgenic plant
US15/481,007 US20180057547A1 (en) 1999-10-01 2017-04-06 Diagnostic and therapeutic epitope, and transgenic plant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923306.6A GB9923306D0 (en) 1999-10-01 1999-10-01 Diagnostic and therapeutic epitope, and transgenic plant
GB9923306.6 1999-10-01

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/089,700 A-371-Of-International US7144569B1 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope
US10089700 A-371-Of-International 2000-10-02
US11/556,208 Continuation US8329144B2 (en) 1999-10-01 2006-11-03 Diagnostic and therapeutic epitope, and transgenic plant
US11/556,218 Division US7888460B2 (en) 1999-10-01 2006-11-03 Diagnostic and therapeutic epitope, and transgenic plant

Publications (2)

Publication Number Publication Date
WO2001025793A2 WO2001025793A2 (en) 2001-04-12
WO2001025793A3 true WO2001025793A3 (en) 2001-08-23

Family

ID=10861989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003760 WO2001025793A2 (en) 1999-10-01 2000-10-02 Diagnosis of coeliac disease using a gliadin epitope

Country Status (15)

Country Link
US (5) US7144569B1 (en)
EP (2) EP1672368B1 (en)
JP (4) JP4932112B2 (en)
AT (2) ATE449965T1 (en)
AU (1) AU782262B2 (en)
CA (1) CA2386089C (en)
CY (2) CY1105282T1 (en)
DE (2) DE60043402D1 (en)
DK (2) DK1672368T3 (en)
ES (2) ES2335895T3 (en)
GB (1) GB9923306D0 (en)
HK (1) HK1088068A1 (en)
MX (1) MXPA02003295A (en)
PT (2) PT1218751E (en)
WO (1) WO2001025793A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
EP2409711B1 (en) 2002-02-14 2018-11-21 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CA2502700C (en) 2002-11-20 2017-01-17 Chaitan Khosla Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
EP1711604B1 (en) * 2004-01-09 2011-10-05 Ottawa Health Research Institute Diabetogenic epitopes
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
MXPA06012322A (en) * 2004-04-28 2007-01-31 Btg Int Ltd Epitopes related to coeliac disease.
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
CN101420973A (en) * 2006-03-15 2009-04-29 埃索谢尔制药公司 Pharmaceutical compositions comprising SODs and prolamine based peptide fragments
US7576040B2 (en) * 2007-01-11 2009-08-18 Halliburton Energy Services, Inc. Cement compositions comprising humic acid grafted fluid loss control additives
CA2680590C (en) 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
JP5855828B2 (en) 2007-08-13 2016-02-09 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Barley with low levels of hordein
WO2010060155A1 (en) 2008-11-30 2010-06-03 Nexpep Pty Ltd Compositions and methods for treatment of celiac disease
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103430025B (en) * 2011-01-20 2017-12-26 西瑞斯实验室有限公司 Detection glutelin sensitiveness distinguishes over the method and apparatus of chylous diarrhea with it
EP2673292A4 (en) * 2011-02-08 2014-05-21 Phadia Ab Wheat antigens and peptides for diagnosis of wheat induced hypersensitivity
WO2012162697A1 (en) * 2011-05-26 2012-11-29 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
US20160091491A1 (en) * 2013-05-02 2016-03-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
US20160145636A1 (en) * 2013-05-08 2016-05-26 Jm Biologicals Compositions and methods for the production of gluten free food products
WO2014191839A2 (en) * 2013-05-14 2014-12-04 Oslo Universitetssykehus Hf Detection of gluten-specific t-cells
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2015140648A2 (en) 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3134735A4 (en) 2014-04-24 2018-06-20 Immusant Inc. Methods of measuring antigen-specific t cells
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
EP3221344A2 (en) 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
DE102015204012A1 (en) 2015-03-05 2016-09-08 Clariant International Ltd. SCR catalyst with improved adhesion
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
US20200002709A1 (en) * 2016-09-01 2020-01-02 Cellectis Methods for altering amino acid content in plants
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN110128549B (en) * 2019-05-27 2021-07-06 深圳市亚辉龙生物科技股份有限公司 Deamidated gliadin polypeptide recombinant antigen, recombinant antigen expression gene, recombinant expression vector, and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459355A (en) 1982-07-12 1984-07-10 International Paper Company Method for transforming plant cells
US4536475A (en) 1982-10-05 1985-08-20 Phytogen Plant vector
NL8300698A (en) 1983-02-24 1984-09-17 Univ Leiden METHOD FOR BUILDING FOREIGN DNA INTO THE NAME OF DIABIC LOBAL PLANTS; AGROBACTERIUM TUMEFACIENS BACTERIA AND METHOD FOR PRODUCTION THEREOF; PLANTS AND PLANT CELLS WITH CHANGED GENETIC PROPERTIES; PROCESS FOR PREPARING CHEMICAL AND / OR PHARMACEUTICAL PRODUCTS.
JPS6047683A (en) 1983-08-24 1985-03-15 Kirin Brewery Co Ltd Promoter
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
DK162399C (en) * 1986-01-28 1992-03-23 Danisco PROCEDURE FOR EXPRESSION OF GENES IN BELGIUM PLANT CELLS, DNA FRAGMENT, RECOMBINED DNA FRAGMENT AND PLASMID FOR USE IN EXERCISING THE PROCEDURE
ES2018274T5 (en) 1986-03-11 1996-12-16 Plant Genetic Systems Nv VEGETABLE CELLS RESISTANT TO GLUTAMINE SYNTHETASE INHIBITORS, PREPARED BY GENETIC ENGINEERING.
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5187073A (en) 1986-06-30 1993-02-16 The University Of Toledo Process for transforming gramineae and the products thereof
US5177010A (en) 1986-06-30 1993-01-05 University Of Toledo Process for transforming corn and the products thereof
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0267159A3 (en) 1986-11-07 1990-05-02 Ciba-Geigy Ag Process for the genetic modification of monocotyledonous plants
US4866247A (en) 1986-12-11 1989-09-12 The Lincoln Electric Company Apparatus and method of short circuiting arc welding
US4971908A (en) 1987-05-26 1990-11-20 Monsanto Company Glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthase
US5356799A (en) * 1988-02-03 1994-10-18 Pioneer Hi-Bred International, Inc. Antisense gene systems of pollination control for hybrid seed production
US5371014A (en) 1988-02-12 1994-12-06 Daicel Chemical Industries, Ltd. Process for the production of optically active 2-hydroxy acid esters using microbes to reduce the 2-oxo precursor
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5250515A (en) * 1988-04-11 1993-10-05 Monsanto Company Method for improving the efficacy of insect toxins
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5428146A (en) * 1988-11-07 1995-06-27 Max-Planck-Gesellschaft Zur Forderung Wound-stimulated DNA-sequence from solanum tuberosum and its use
US5110732A (en) * 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
US5086169A (en) * 1989-04-20 1992-02-04 The Research Foundation Of State University Of New York Isolated pollen-specific promoter of corn
US5629183A (en) * 1989-05-08 1997-05-13 The United States Of America As Represented By The Secretary Of Agriculture Plant transformation by gene transfer into pollen
US5097025A (en) * 1989-08-01 1992-03-17 The Rockefeller University Plant promoters
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
EP0814166A3 (en) 1989-08-09 1998-05-13 DeKalb Genetics Corporation Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof
WO1991006648A1 (en) * 1989-10-27 1991-05-16 The Salk Institute For Biological Studies Glutamate receptor compositions and methods
US5589583A (en) 1990-01-11 1996-12-31 Monsanto Company Plant promoter
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
HU220773B1 (en) 1990-01-22 2002-05-28 Dekalb Genetics Corporation Process for producing productive transgenic maize plants
EP0442174A1 (en) 1990-02-13 1991-08-21 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
US5618988A (en) 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5187267A (en) * 1990-06-19 1993-02-16 Calgene, Inc. Plant proteins, promoters, coding sequences and use
AU655197B2 (en) 1990-06-25 1994-12-08 Monsanto Technology Llc Glyphosate tolerant plants
NZ239977A (en) 1990-11-14 1993-08-26 Pioneer Hi Bred Int Transforming plants by the use of agrobacterium
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
WO1992009587A1 (en) 1990-11-26 1992-06-11 E.I. Du Pont De Nemours And Company Herbicidal oxazine ethers
US5459252A (en) 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
AU1202192A (en) 1991-02-07 1992-09-07 Plant Genetic Systems N.V. Stamen-specific promoters from corn
IL101508A0 (en) 1991-04-08 1992-12-30 Rhone Poulenc Agrochimie Chimeric plant genes based on upstream regulatory elements of helianthinin
ES2163400T3 (en) 1991-05-15 2002-02-01 Monsanto Technology Llc METHOD OF CREATING A TRANSFORMED RICE PLANT.
WO1993004178A1 (en) 1991-08-23 1993-03-04 University Of Florida A novel method for the production of transgenic plants
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
AU675678B2 (en) 1992-10-29 1997-02-13 Prolifix Limited Transcription factor DP-1
US5389226A (en) 1992-12-17 1995-02-14 Amorphous Technologies International, Inc. Electrodeposition of nickel-tungsten amorphous and microcrystalline coatings
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1994025613A1 (en) 1993-05-03 1994-11-10 Cornell Research Foundation, Inc. Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
US5670349A (en) 1993-08-02 1997-09-23 Virginia Tech Intellectual Properties, Inc. HMG2 promoter expression system and post-harvest production of gene products in plants and plant cell cultures
WO1995006722A1 (en) 1993-09-03 1995-03-09 Japan Tobacco Inc. Method of transforming monocotyledon by using scutellum of immature embryo
WO1995019030A1 (en) * 1994-01-05 1995-07-13 Pois, Inc. Apparatus and method for a personal onboard information system
US5495007A (en) 1994-04-29 1996-02-27 Thompson; Gary A. Phloem-specific promoter
US5459007A (en) * 1994-05-26 1995-10-17 Xerox Corporation Liquid developer compositions with block copolymers
US5633363A (en) 1994-06-03 1997-05-27 Iowa State University, Research Foundation In Root preferential promoter
US5646333A (en) * 1994-09-02 1997-07-08 Drexel University Plant promoter useful for directing the expression of foreign proteins to the plant epidermis
HUT76355A (en) 1995-11-24 1997-08-28 Bay Zoltan Alkalmazott Kutatas Plant gene-expression vector family based on dna fragments regulating alfalfa h3 histon gene variant (ms h3g1)
US6036983A (en) 1996-05-20 2000-03-14 Novo Nordisk A/S Method of obtaining protein hydrolysates
WO1997047647A1 (en) 1996-06-13 1997-12-18 Consejo Superior De Investigaciones Cientificas Plant proteins
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US5959175A (en) 1997-04-09 1999-09-28 Thomas; Terry L. Sunflower albumin 5' regulatory region for the modification of plant seed lipid composition
US5977436A (en) 1997-04-09 1999-11-02 Rhone Poulenc Agrochimie Oleosin 5' regulatory region for the modification of plant seed lipid composition
ES2132025B1 (en) 1997-06-12 2000-12-01 Consejo Superior Investigacion URAG PROTEINS OF PLANTS.
US6100450A (en) 1997-10-22 2000-08-08 Rhone-Poulenc Agrochimie Seed specific promoters based on arabidopsis genes
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
WO1999053069A2 (en) 1998-04-09 1999-10-21 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins cdc2 and pitslre from plants
JP2002514423A (en) 1998-05-08 2002-05-21 コンセホ・スペリオル・デ・インヴェスティガシオンス・シエンティフィカス Transgenic plant cells expressing recombinant plant E2F peptide
AU3230200A (en) 1999-02-12 2000-08-29 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
MXPA03009313A (en) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides.
DE60221700T2 (en) * 2001-12-11 2008-04-30 Tagsys S.A. SYSTEMS FOR SAFELY MARKING DATA
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
EP2409711B1 (en) * 2002-02-14 2018-11-21 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CA2502700C (en) * 2002-11-20 2017-01-17 Chaitan Khosla Diagnostic method for celiac sprue
US7144567B2 (en) * 2002-12-16 2006-12-05 Erling Jim Andersen Renewable energy carrier system and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDERSON ROBERT P ET AL: "In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.", NATURE MEDICINE, vol. 6, no. 3, March 2000 (2000-03-01), pages 337 - 342, XP000982628, ISSN: 1078-8956 *
ARENTZ-HANSEN, HELENE ET AL: "The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase", J. EXP. MED., vol. 191, no. 4, 21 February 2000 (2000-02-21), pages 603 - 612, XP000986723 *
DATABASE SWISSPROT 13 August 1987 (1987-08-13), XP002161985 *
GODKIN A J ET AL: "Identification of a coeliac disease-specific T cell epitope from A-gliadin.", GUT, vol. 44, no. SUPPL. 1, April 1999 (1999-04-01), British Society of Gastroenterology Annual Meeting;Glasgow, Scotland, UK; March 23-25, 1999, pages A72, XP000989626, ISSN: 0017-5749 *
O'KEEFFE J ET AL: "T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC).", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08-01), pages 269 - 276, XP000989621, ISSN: 0009-9104 *
OKITA T W ET AL: "EVOLUTION AND HETEROGENEITY OF THE ALPHA-BETA-TYPE AND GAMMA-TYPE GLIADIN DNA SEQUENCES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 13, 1985, pages 8203 - 8213, XP000982597, ISSN: 0021-9258 *
TRONCONE R ET AL: "Cytokines produced by gliadin-specific T cell clones from the coeliac mucosa.", GASTROENTEROLOGY, vol. 110, no. 4 SUPPL., April 1996 (1996-04-01), 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week;San Francisco, California, USA; May 19-22, 1996, pages A1031, XP000989625, ISSN: 0016-5085 *
UHLIG H ET AL: "Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies.", AUTOIMMUNITY, (1998) 28 (4) 185-95., XP002118954 *
VAN DE WAL YVONNE ET AL: "Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 17, 18 August 1998 (1998-08-18), Aug. 18, 1998, pages 10050 - 10054, XP000982626, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics

Also Published As

Publication number Publication date
CY1105282T1 (en) 2010-03-03
ATE319091T1 (en) 2006-03-15
EP1218751B1 (en) 2006-03-01
AU7539400A (en) 2001-05-10
ES2256042T3 (en) 2006-07-16
US20080175971A1 (en) 2008-07-24
JP2010263898A (en) 2010-11-25
DK1672368T3 (en) 2010-01-04
CA2386089A1 (en) 2001-04-12
US20090269285A1 (en) 2009-10-29
ES2335895T3 (en) 2010-04-06
JP5371890B2 (en) 2013-12-18
US7888460B2 (en) 2011-02-15
ATE449965T1 (en) 2009-12-15
EP1672368B1 (en) 2009-11-25
US20110044912A2 (en) 2011-02-24
EP1218751A2 (en) 2002-07-03
JP6139154B2 (en) 2017-05-31
PT1672368E (en) 2010-01-20
DE60043402D1 (en) 2010-01-07
JP2013126991A (en) 2013-06-27
US20180057547A1 (en) 2018-03-01
AU782262B2 (en) 2005-07-14
JP2003511670A (en) 2003-03-25
MXPA02003295A (en) 2002-09-02
US20130318648A1 (en) 2013-11-28
CY1109837T1 (en) 2014-09-10
JP2016164169A (en) 2016-09-08
PT1218751E (en) 2006-06-30
GB9923306D0 (en) 1999-12-08
HK1088068A1 (en) 2006-10-27
US8329144B2 (en) 2012-12-11
WO2001025793A2 (en) 2001-04-12
EP1672368A1 (en) 2006-06-21
US7144569B1 (en) 2006-12-05
DE60026332T2 (en) 2006-08-10
JP4932112B2 (en) 2012-05-16
DE60026332D1 (en) 2006-04-27
DK1218751T3 (en) 2006-07-03
CA2386089C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
WO2001025793A3 (en) Diagnosis of coeliac disease using a gliadin epitope
EP0175360A3 (en) Peptide antibodies and their use in detecting oncogene products
WO1999050282A3 (en) Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
Lu et al. Primary structure of human triosephosphate isomerase.
Gainer Precursors of vasopressin and oxytocin
US20070161545A1 (en) Triple polypeptide complexes
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
KR970706306A (en) Peptides and pharmaceutical compositions comprising them
Metters et al. Selective cleavage of proenkephalin-derived peptides (less than 23,300 daltons) by plasma kallikrein.
Börchers et al. Revision of the amino acid sequence of human heart fatty acid-binding protein
AU2002339227A1 (en) Triple polypeptide complexes
HUT77262A (en) New immunocontraceptive peptides
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
AU6393990A (en) Hiv related peptides
Sanger Les Prix Nobel en 1958
WO2001096400A3 (en) 52871, a novel human g protein coupled receptor and uses thereof
Konami et al. A putative carbohydrate-binding domain of the lactosebinding Cytisus sessilifolius anti-H (O) lectin has a similar amino acid sequence to that of the l-fucose-binding Ulex europaeus anti-H (O) lectin
MORODER et al. Studies on Immunoassays of Peptide Factors. II. Fluorescence Enzyme Immunoassay for Human Little-Gastrin
Martzen et al. Aspartic protease inhibitors from the parasitic nematode Ascaris
SCHMID The Elucidation of the Amino Acid Sequence of Proteins and Glycoproteins
WO2001042423A3 (en) Compositions and methods for detecting stress-inducible proteins
Sanger Les Prix Nobel en
HARRIS THE CHEMICAL STRUCTURE OF MSHS
Knodrashina et al. Isolation and immunochemical characterization of soluble membrane proteins of the cell walls of diphtheria corynebacteria.
Leng Precursors of Vasopressin and Oxytocin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386089

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 528704

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003295

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000964460

Country of ref document: EP

Ref document number: 75394/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000964460

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 75394/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000964460

Country of ref document: EP